Posted 8th July 2020 by Joshua Sewell
Extracellular vesicles provide an exciting opportunity as a modality for non-invasive biomarkers, which may enable them to be used as biomarkers for tumour metastasis.
Posted 1st July 2020 by Liv Sewell
“By failing to prepare, you are preparing to fail” so said Benjamin Franklin, and as a veteran of early stage drug discovery you can bet that I, like you, have seen my fair share of successes but also more failures than I’d like.
Posted 24th June 2020 by Joshua Sewell
We spoke with Dr David Guttery about his pioneering work using circulating tumour DNA to enable early detection, monitoring and therapeutic decision making for better patient outcomes in gynaecological cancers.
Posted 17th June 2020 by Liv Sewell
Almost five years ago, the plan to implement a wide-ranging digital pathology approach across the Netherlands began to take shape. As more labs across the country acquire digital pathology capability, with steps to create a strong and accessible image repository and a national image exchange platform, one of the project leaders, Professor Katrien Grünberg, offered an update and spoke of some challenges that still lie ahead.
Posted 10th June 2020 by Liv Sewell
Bringing molecular and digital pathology closer together through a more integrative approach can lead to clear advantages for diagnostic and research workflows.
Posted 3rd June 2020 by Liv Sewell
Computational pathology has increased applications for diagnosis, prediction of prognosis and therapy response, facilitating the movement of healthcare towards personalised medicine.
Coupled with deep learning, such tools are ever more efficient and robust within research and clinical settings.
Posted 27th May 2020 by Liv Sewell
The present COVID-19 crisis has demonstrated the vital need for knowledge sharing across the global science community. We asked three of our speakers what international collaboration means for them as leaders in their fields.
Posted 20th May 2020 by Joshua Sewell
This article is republished with kind permission from BioVox.
Recent activities in the cell therapy field have prompted many investment funds to pour fresh and increasing capital into this space. In this review, we would like to share some observations and highlight a few of the questions that arise when new modalities cross the bridge from bench to bed.